Only ground-breaking projects are selected
Each of OvaCure’s projects is conducted by world-leading experts within the fields of immunotherapy, oncology and gynecology and is guided by OvaCure’s Scientific and Clinical Advisory Board.
In collaboration with the Anticancer Fund and the OvaCure Scientific and the Clinical Advisory Board, OvaCure has generated a project portfolio of two Danish and three international projects. Each project developed through OvaCure has maximum potential for curative treatments of ovarian cancer patients.
OvaCure' five projects are currently underway, with the flagship project, T-cell Infusion being among the world's first trials to treat ovarian cancer patients with adoptive T-cell therapy (ACT). OvaCure’s second project, T-cell Combination, will be conducted under the same clinical trial protocol with modifications to further the investigation by combining ACT with IFNα and chemotherapy. These two projects are the result of the OvaCure Innovation Summit in 2014, and have inspired the development of two additional international projects in Lausanne, which aim to develop novel personalised vaccination programs for ovarian cancer patients. OvaCure's Innovation Summits and Collaboration Labs in 2016 have also initiated, co-created and developed two additional projects, Tumour-Match and CAR T-cell Projects.
Learn more about OvaCure projects
T-cell Infusion Project (Denmark)
Original title: “Immunotherapy by adoptive T-cell infusion in the event of advanced ovarian cancer (stage III and IV) and treatment trials for a total of 18 women”.
The project is conducted at the Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital Herlev, Copenhagen, Denmark. Principal investigator: Head of OvaCure Immunotherapy Dream Collaboration, Professor Inge Marie Svane, MD, PhD.
- Ovarian cancer patients in this trial are among the first in the world to be treated with T-cells
- Centre for Cancer Immune Therapy in Copenhagen is a world leader in T-cell therapy
- 55% success rate in melanoma with this method already Proven Project lead, Prof. Inge Marie Svane is a pioneer in Adoptive T-cell therapy
T-cell Combination Therapy Project (The Netherlands)
Original title: “Combined chemo and adoptive T-cell therapy (ACT) as treatment for recurrent epithelial ovarian carcinoma”.
This project is conducted at the Leiden University Medical Center, Leiden, the Netherlands. Principal investigator: Assoc. Professor Els M. E. Verdegaal, PhD.
- Aims to provide a lower toxicity treatment regimen for ovarian cancer patients
- Stands to improve T-cell function after re-infusion using chemotherapy and Interferon alpha
Personal T-Cell Project (Switzerland)
Original title: “Harnessing tumour diversity to develop personalised adoptive immunotherapy for ovarian cancer”.
This pre-clinical project is conducted at the Ludwig Center for Cancer Research, University of Lausanne, Switzerland. Principal investigator: Professor George Coukos, MD, PhD.
- Harnessing the diversity and micro-environment of the patients’ tumour
- Establishing robust pre-clinical methods for application in a clinical setting
Personal Vaccine Project (Switzerland)
Original title: "A Phase I/II study to test the feasibility, safety and immunogenicity of personalised mutanome peptide (PMP) vaccine vs. whole tumour oxidized lysate (OC-L) vaccine admixed with CpG adjuvant, in combination with low-dose cyclophosphamide in primary advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer".
This clinical project is conducted at the Ludwig Center for Cancer Research, University of Lausanne, Switzerland. Principal investigator: Professor Lana Kandalaft, MD, PhD.
Making immunotherapy even more personal for ovarian cancer
- Ovarian cancer patients will be administered with two different vaccines approaches
- Project goal is to develop the best vaccine approach as a primary treatment for ovarian cancer
Tumour-Match Project (Denmark)
Original title: ”Molecular profiling ovarian cancer patient subpopulations - beyond BRCA1/2”.
This project will be conducted at Nordic Society of Gyneacological Oncology at Rigshospitalet, Denmark. Principal investigator: Dr. Mansoor Raza Mirza, MD, Chief Oncologist.
- A retrospective study
- Project identifies patients who respond to different combinations of cancer treatments and uses this to improve patient stratification
- Economic and health benefits of administering treatment that is matched to a patient’s tumour-profile
CAR-T cell therapy (USA)
Original title: “CAR-T cell therapy in ovarian cancer patients”
This project will be conducted at University of Pennsylvania, USA. Principal Investigator: Assoc. Professor Daniel Powell, PhD.
- Aims to assess the feasibility and tolerability of treating ovarian cancer patients with 3rd generation CAR-T cells.
- Strives to improve targeting efficacy and persistence of previous CAR-T approaches in ovarian cancer patients.